Reddy博士从Mercury Pharma公司购买Progynova和Cyclo-Progynova品牌, Dr. Reddy’s buys Progynova and Cyclo-Progynova brands from Mercury Pharma for $32.15M to enter India’s HRT market.

Reddy博士的实验室已经从水星制药集团获得了3 215万美元的印度商标和资产,用于激素替代疗法品牌Progynova和Cyclo-Progynova,标志着印度进入印度高棉市场。 Dr. Reddy’s Laboratories has acquired the Indian trademarks and assets for the hormone replacement therapy brands Progynova and Cyclo-Progynova from Mercury Pharma Group for $32.15 million, marking its entry into India’s HRT market. 截至2025年12月,Progynova是最销的雌激素品牌,销售额达到1亿卢比,治疗雌激素缺乏症并预防更年期后骨质疏松症,而Cyclo-Progynova则结合雌激素和孕激素. Progynova, a top-selling estradiol brand with ₹100 crore in sales as of December 2025, treats estrogen deficiency and prevents postmenopausal osteoporosis, while Cyclo-Progynova combines estrogen and progestogen. 这笔交易加强了Reddy医生的妇科组合,并扩大了其在日益扩大的治疗部分的覆盖范围。 The deal strengthens Dr. Reddy’s gynecology portfolio and expands its reach in a growing therapeutic segment.